SEC Filing Summary
Filing and reporting period: Form 10-Q for the quarter ended September 30, 2016, filed November 10, 2016. The source filing identifies the registrant as Histogenics Corporation, not Ocugen, Inc.; this company-name discrepancy should be verified.
Business Context
Histogenics was a clinical-stage regenerative medicine company developing musculoskeletal tissue-repair products, led by NeoCart, which was in a U.S. Phase 3 clinical trial under an FDA special protocol assessment for knee cartilage damage. The company had not generated revenue from planned principal operations and had never been profitable.
Financial Metrics
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $4.9 million | $5.8 million | $16.3 million | $17.5 million |
| General and administrative expense | $1.8 million | $2.2 million | $6.1 million | $6.0 million |
| Net loss | $9.3 million | $8.1 million | $25.3 million | $23.7 million |
| Loss per common share | $0.70 | $0.61 | $1.90 | $1.79 |
| Cash used in operating activities | Not separately provided | Not separately provided | $19.8 million | $23.0 million |
| Cash and cash equivalents | September 30, 2016: $38.0 million | December 31, 2015: $30.9 million |
At September 30, 2016, total assets were $42.8 million, total liabilities were $38.8 million, and stockholders’ equity was $4.0 million. The accumulated deficit was $190.8 million. Equipment-loan borrowings totaled $907,000, including $583,000 classified as current. The company was in compliance with its debt covenants.
Material Changes Versus Prior Comparable Period
- Third-quarter R&D expense declined 17% to $4.9 million, primarily because of lower consulting, recruiting, raw-material, and patient-recruitment costs.
- Nine-month R&D expense decreased 7% to $16.3 million, while nine-month G&A expense increased 2% to $6.1 million.
- Net loss increased to $9.3 million in the quarter and $25.3 million year to date, despite lower operating expenses, primarily because of private-placement-related warrant and transaction costs.
- Operating cash burn improved by $3.2 million year over year to $19.8 million for the first nine months.
- Cash increased by $7.1 million year to date, compared with a $20.3 million decrease in the prior-year period, due principally to financing proceeds.
Financing, Liquidity, Outlook, and Risks
On September 29, 2016, the company completed a private placement generating $30.0 million of gross proceeds and approximately $27.7 million of net proceeds. It issued 2.6 million common shares, Series A Convertible Preferred Stock convertible into approximately 10.7 million common shares, and warrants to purchase approximately 13.5 million common shares at $2.25 per share, including placement-agent warrants. The warrants were recorded as a liability with a September 30 fair value of $30.2 million, creating significant potential dilution and future fair-value volatility.
Management expected the $38.0 million of cash and cash equivalents to fund projected needs into the middle of 2018, but stated that additional capital would be required to complete a biologics license application, commercialize NeoCart if approved, and develop other candidates. The company expected continued net losses for several years and had no stated revenue or profitability guidance.
- NeoCart Phase 3 enrollment remained a key execution risk; the company had previously moved its expected enrollment-completion target from June 2016 to June 2017 because enrollment trends were below expectations.
- FDA approval, clinical-trial success, manufacturing comparability, facility compliance, production capacity, reimbursement, market acceptance, competition, and intellectual-property protection remained material uncertainties.
- The FDA approved collagen production data in April 2016 and the collagen-scaffold equivalence strategy in August 2016, but could still require additional data or studies.
- Future commitments included potential regulatory and licensing milestones, royalties, lease obligations, and up to $12.0 million of commercialization milestones plus $22.5 million of sales milestones under the Intrexon collaboration, if achieved.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements.
Important Facts for Investors to Verify
- Confirm whether this filing belongs to Histogenics Corporation or Ocugen, Inc.; the supplied filing text consistently names Histogenics.
- Verify the status and enrollment progress of the NeoCart Phase 3 trial and the current FDA pathway toward a biologics license application.
- Assess cash runway against the reported $19.8 million nine-month operating cash burn and the need for additional financing.
- Review the economic effects, conversion limits, registration status, exercise conditions, and dilution potential of the Series A Preferred Stock and approximately 13.5 million warrants.
- Evaluate whether the $30.2 million warrant liability and related fair-value changes could materially affect future reported earnings and equity.
- Review licensing, Intrexon-related obligations, debt covenants, manufacturing-transfer requirements, and potential FDA-imposed studies or delays.